FIND YOUR VIVEVE SOLUTIONS PROVIDER

Thank you for contacting a Viveve Solutions Provider.  A message has been sent to them & they will be following up with you shortly.

 

If you don’t hear back from them within 24 – 48 hours, please let us know HERE.

 

We hope you enjoy your Viveve Solution(s)!

<svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 78 51" style="enable-background:new 0 0 78 51;" xml:space="preserve"> .st0{fill:#C1D831;} .st1{fill:#FFFFFF;}
<svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 811.1 169.5" style="enable-background:new 0 0 811.1 169.5;" xml:space="preserve"> .st0{fill:#C2D500;} <path class="st0" d="M81.3,166.4H61L0,2.7l2.2-0.6c0.2,0,16.6-4.2,24,13l45,120.3l45-120.3c7.5-17.3,23.9-13.1,24-13.1l2.2,0.6 L81.3,166.4z"/> <path class="st0" d="M302.7,166.4h-20.3l-61-163.7l2.2-0.6c0.2,0,16.6-4.2,24,13l44.9,120.3l45-120.3C345-2.2,361.4,1.9,361.5,2 l2.2,0.6L302.7,166.4z"/> <path class="st0" d="M602.3,166.4H582L521,2.7l2.2-0.6c0.2,0,16.6-4.2,24,13l45,120.3l45-120.3C644.6-2.3,661,1.9,661.1,2 l2.2,0.6L602.3,166.4z"/> <path class="st0" d="M789.7,130.3h21.4c0,0-1.6,7.5-5.6,12.9l-1,1.4c-12,15.9-33.1,25-57.6,25c-0.4,0-0.9,0-1.3,0 c-26.2,0-47.8-10.6-59.5-29.1c-11-17.2-12.4-38.6-12.4-55.4c0-18.2,1.5-39.1,12.4-55.8C698.2,10.1,718,0,743.5,0 c22.7,0,41.2,10.1,53.7,29.1c8.8,14.3,9.7,37,9.7,46.1v15.5h-93.2l1.2-2.8c5.2-12.8,18.4-17.4,29-17.4h0.1h42.4 c-0.2-10.2-2-23.5-6.4-30.4c-8.7-13.5-20.3-19.8-36.5-19.8c-18.7,0-32.4,6.7-40.5,19.8c-14.7,23.6-10.7,73,0,89.4 c8.1,12.4,24.6,19.9,43.9,19.9c18.1,0,33.2-6.3,41.6-17.3L789.7,130.3"/> <path class="st0" d="M488.9,130.3h21.4c0,0-1.6,7.5-5.6,12.9l-1,1.4c-12,15.9-33.1,25-57.6,25c-0.4,0-0.9,0-1.3,0 c-26.2,0-47.8-10.6-59.5-29.1c-11-17.2-12.4-38.6-12.4-55.4c0-18.2,1.5-39.1,12.4-55.8c12.1-19,32-29.1,57.4-29.1 c22.7,0,41.2,10.1,53.7,29.1c8.8,14.3,9.7,37,9.7,46.1v15.5h-93.2l1.2-2.8c5.2-12.8,18.4-17.4,29-17.4h0.1h42.4 c-0.2-10.2-2-23.5-6.4-30.4c-8.7-13.5-20.3-19.8-36.5-19.8c-18.7,0-32.4,6.7-40.5,19.8c-14.7,23.6-10.7,73,0,89.4 c8.1,12.4,24.6,19.9,43.9,19.9c18.1,0,33.2-6.3,41.6-17.3L488.9,130.3"/>

345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112

<svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="24" height="24" viewBox="0 0 32 32" style="fill:#c4d600;"><svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="24" height="24" viewBox="0 0 32 32" style="fill:#c4d600;"><svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="24" height="24" viewBox="0 0 16 16" style="fill:#c4d600;"><svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="25" height="25" viewBox="0 0 50 50" style="fill:#c4d600;">

 

Content provided on this site may not be applicable for every region. Please abide by your regional indication as follows: The Viveve System® is indicated for treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function in: Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Malaysia, Mexico, Panama, Philippines, Singapore, United Arab Emirates, Uruguay, and Venezuela. The Viveve System is indicated for treatment of vaginal laxity in: Bahrain, EU, Iceland, Iran, Korea, Kuwait, Lebanon, Liechtenstein, Norway, Qatar, South Africa, Switzerland, Turkey, and Ukraine. The Viveve System is indicated for use in general surgery for electrocoagulation and hemostasis in: Korea, Peru, Taiwan, Thailand, and the United States.
Manage Your Listing
Viveve, Inc. 2019 All Rights Reserved